<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00417612</url>
  </required_header>
  <id_info>
    <org_study_id>P50AR054086</org_study_id>
    <secondary_id>P50AR054086</secondary_id>
    <secondary_id>1P50AR054086-01</secondary_id>
    <nct_id>NCT00417612</nct_id>
  </id_info>
  <brief_title>Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets</brief_title>
  <official_title>The Role of Parathyroid Hormone in the Pathogenesis of Skeletal Disease in X-linked Hypophosphatemic Rickets (XLH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of paricalcitol, a form of
      synthetic vitamin D, in lowering parathyroid hormone (PTH) levels and reducing disease
      symptoms in children and adults with X-linked hypophosphatemic (XLH) rickets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      XLH rickets is a rare inherited disorder in which the bones become painfully soft and bend
      easily because of a phosphate deficiency. This genetic defect causes the kidneys to allow
      excretion of an inappropriately high amount of phosphate into the urine. The kidneys are also
      unable to convert vitamin D into a form usable by the body, resulting in inadequate amounts
      of active vitamin D. Because vitamin D is needed to absorb calcium and phosphate from the
      intestine, this deficiency further reduces phosphate levels. Without the sufficient phosphate
      needed for normal bone growth, individuals with XLH rickets typically develop skeletal
      malformations, bone pain, and abnormally bowed legs. Hyperparathyroidism, a condition in
      which the parathyroid glands excrete excess amounts of PTH, also occurs frequently in
      individuals with XLH rickets, and may play a significant role in the skeletal complications
      associated with XLH rickets. The purpose of this study is to determine the effectiveness of
      paricalcitol in lowering PTH levels and reducing disease symptoms in individuals with XLH
      rickets.

      This study will last 12 months. Participants will be randomly assigned to receive either
      paricalcitol or placebo, taken in the form of two pills daily for the duration of the study.
      During a baseline 3-day inpatient hospital stay, participants will undergo a physical exam, a
      cardiac ultrasound, a bone scan, blood collection, and a radiographic skeletal survey. The
      skeletal survey will include x-rays of various body parts. Participants who are 18 years or
      younger will not undergo the radiographic skeletal survey. Study visits for all participants
      will occur every 2 months until the end of the study. These visits will include a physical
      exam, review of disease symptoms, blood and urine collection, and a check of medication
      compliance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
    <description>Mean area under the curve for parathyroid hormone levels (PTHauc) sampled during a 26 hour study period, for Paricalcitol (Active Drug) and Placebo groups at Baseline and Month 12 .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve for Parathyroid Hormone (PTH; Percentage Decrease)</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
    <description>Mean PTHauc (% decrease) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of Parathyroid Hormone Area Under the Curve (PTHauc) of 20% or Greater</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
    <description>Clinically significant reduction of Mean PTHauc (% decrease &gt;/= 20) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Static Parameters of Serum Alkaline Phosphatase at Baseline and 1 Year for Paricalcitol and Placebo Arms.</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Scan Severity Score</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
    <description>99-Tc-methylenediphosphonate bone scans were completed and analyzed using the following scale*: Bone scan severity scale with minimum score of 0 and maximum score of 4 (0 is no disease and 4 is greatest severity of disease).
Appearance of lumbar spine and the sacroiliac region were used as internal references to which all suspected lesions were compared, and scored as follows:
grade 0, normal scan without suspicious lesions grade 1, lesion(s) less intense than normal lumbar spine grade 2, lesion(s) similar in intensity to normal lumbar spine grade 3, lesions more intense than normal lumbar spine but similar to the normal sacroiliac region grade 4, lesions more intense than the normal sacroiliac region.
*devised by nuclear medicine radiologist at Yale New Haven Hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Urinary Calcium Excretion From Baseline to 1 Year</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
    <description>Percent change in daily urinary calcium excretion, which is calculated the measurements of the calcium in the subject's 24-hr urine collections done at baseline and at the 1 year timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Intact Fibroblast Growth Factor 23 (FGF23)</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 1,25 (OH)2D</measure>
    <time_frame>Measured at baseline and Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypophosphatemia, Familial</condition>
  <condition>Hyperparathyroidism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants given placebo capsule to match for comparison</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paricalcitol</intervention_name>
    <description>Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zemplar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sugar pill</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of XLH rickets

          -  Fasting serum calcium of 10.7 mg/dl or less

          -  Fasting PTH greater than 40 nleq/ml and less than 120 nleq/ml in the mid-molecule PTH
             assay at screening (upper limit of normal is 25 nleq/ml)

          -  Willing and able to participate in the trial

          -  Taking stable dose of standard therapy for XLH rickets for at least 2 months prior to
             study entry

          -  Concomitant therapy for XLH rickets will not be an exclusion criteria

          -  Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

          -  Concomitant kidney failure (estimated creatinine clearance less than 60 cc/min or
             serum creatinine greater than 1.5 mg/dl)

          -  Serum 25-hydroxy vitamin D less than 20 ng/ml. Participants meeting this criterion
             will receive vitamin D3 supplementation for 3 months and then be rescreened.

          -  Unable to comply with protocol and appropriate follow-up visits

          -  Treatment with agents that may affect skeletal metabolism, such as glucocorticoids and
             anticonvulsants
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas O. Carpenter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17 Suppl 10:10-9. Review.</citation>
    <PMID>12386264</PMID>
  </reference>
  <reference>
    <citation>McElduff A, Posen S. Parathyroid hormone sensitivity in familial X-linked hypophosphatemic rickets. J Clin Endocrinol Metab. 1989 Aug;69(2):386-9.</citation>
    <PMID>2753981</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2006</study_first_submitted>
  <study_first_submitted_qc>December 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2007</study_first_posted>
  <results_first_submitted>August 2, 2014</results_first_submitted>
  <results_first_submitted_qc>October 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 28, 2014</results_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Thomas Carpenter</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Rickets, Hypophosphatemia</keyword>
  <keyword>Rickets, Vitamin D-Resistant</keyword>
  <keyword>Rickets, X-linked hypophosphatemic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Hypophosphatemia</mesh_term>
    <mesh_term>Rickets, Hypophosphatemic</mesh_term>
    <mesh_term>Familial Hypophosphatemic Rickets</mesh_term>
    <mesh_term>Hypophosphatemia, Familial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paricalcitol (Active Drug)</title>
          <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce Parathyroid Hormone (PTH) level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Errant diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Paricalcitol (Active Drug)</title>
          <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement</title>
        <description>Mean area under the curve for parathyroid hormone levels (PTHauc) sampled during a 26 hour study period, for Paricalcitol (Active Drug) and Placebo groups at Baseline and Month 12 .</description>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Parathyroid Hormone (PTHauc) Measurement</title>
          <description>Mean area under the curve for parathyroid hormone levels (PTHauc) sampled during a 26 hour study period, for Paricalcitol (Active Drug) and Placebo groups at Baseline and Month 12 .</description>
          <units>nlEq*26hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1223" spread="426"/>
                    <measurement group_id="O2" value="1449" spread="865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="987" spread="372"/>
                    <measurement group_id="O2" value="1616" spread="945"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Static Parameters of Serum Alkaline Phosphatase at Baseline and 1 Year for Paricalcitol and Placebo Arms.</title>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <population>Alkaline phosphatase activity was analyzed separately for children (less than 18 years of age) and adults as values varied considerably between these two groups. In other outcome measure modules the paricalcitol group is comprised of 19 participants analyzed which includes adults and children. In this module, the children (2) are their own arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
          <group group_id="O3">
            <title>Paricalcitol (Children Ages 9-17)</title>
            <description>Pediatric patients ages 9-17 given paricalcitol</description>
          </group>
        </group_list>
        <measure>
          <title>Static Parameters of Serum Alkaline Phosphatase at Baseline and 1 Year for Paricalcitol and Placebo Arms.</title>
          <population>Alkaline phosphatase activity was analyzed separately for children (less than 18 years of age) and adults as values varied considerably between these two groups. In other outcome measure modules the paricalcitol group is comprised of 19 participants analyzed which includes adults and children. In this module, the children (2) are their own arm.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Alkaline Phosphatase (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141" spread="96"/>
                    <measurement group_id="O2" value="96" spread="28"/>
                    <measurement group_id="O3" value="354" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Alkaline Phosphatase (1 Year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="70"/>
                    <measurement group_id="O2" value="98" spread="34"/>
                    <measurement group_id="O3" value="402" spread="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium</title>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Calcium (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="0.5"/>
                    <measurement group_id="O2" value="9.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Calcium (1 Year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="0.5"/>
                    <measurement group_id="O2" value="9.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Scan Severity Score</title>
        <description>99-Tc-methylenediphosphonate bone scans were completed and analyzed using the following scale*: Bone scan severity scale with minimum score of 0 and maximum score of 4 (0 is no disease and 4 is greatest severity of disease).
Appearance of lumbar spine and the sacroiliac region were used as internal references to which all suspected lesions were compared, and scored as follows:
grade 0, normal scan without suspicious lesions grade 1, lesion(s) less intense than normal lumbar spine grade 2, lesion(s) similar in intensity to normal lumbar spine grade 3, lesions more intense than normal lumbar spine but similar to the normal sacroiliac region grade 4, lesions more intense than the normal sacroiliac region.
*devised by nuclear medicine radiologist at Yale New Haven Hospital</description>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Scan Severity Score</title>
          <description>99-Tc-methylenediphosphonate bone scans were completed and analyzed using the following scale*: Bone scan severity scale with minimum score of 0 and maximum score of 4 (0 is no disease and 4 is greatest severity of disease).
Appearance of lumbar spine and the sacroiliac region were used as internal references to which all suspected lesions were compared, and scored as follows:
grade 0, normal scan without suspicious lesions grade 1, lesion(s) less intense than normal lumbar spine grade 2, lesion(s) similar in intensity to normal lumbar spine grade 3, lesions more intense than normal lumbar spine but similar to the normal sacroiliac region grade 4, lesions more intense than the normal sacroiliac region.
*devised by nuclear medicine radiologist at Yale New Haven Hospital</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Scan Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.18" spread="1.19"/>
                    <measurement group_id="O2" value="2.00" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Scan Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="1.25"/>
                    <measurement group_id="O2" value="2.12" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Urinary Calcium Excretion From Baseline to 1 Year</title>
        <description>Percent change in daily urinary calcium excretion, which is calculated the measurements of the calcium in the subject's 24-hr urine collections done at baseline and at the 1 year timepoints</description>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Urinary Calcium Excretion From Baseline to 1 Year</title>
          <description>Percent change in daily urinary calcium excretion, which is calculated the measurements of the calcium in the subject's 24-hr urine collections done at baseline and at the 1 year timepoints</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253" spread="388"/>
                    <measurement group_id="O2" value="9" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Intact Fibroblast Growth Factor 23 (FGF23)</title>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Intact Fibroblast Growth Factor 23 (FGF23)</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum Intact FGF23 (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="72" upper_limit="203"/>
                    <measurement group_id="O2" value="93" lower_limit="46" upper_limit="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum Intact FGF23 (1 Year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" lower_limit="145" upper_limit="411"/>
                    <measurement group_id="O2" value="104" lower_limit="47" upper_limit="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum 1,25 (OH)2D</title>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Serum 1,25 (OH)2D</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum 1,25(OH)2D (Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="18"/>
                    <measurement group_id="O2" value="47" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum 1,25 (OH)2D (1 Year)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52" spread="17"/>
                    <measurement group_id="O2" value="46" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve for Parathyroid Hormone (PTH; Percentage Decrease)</title>
        <description>Mean PTHauc (% decrease) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.</description>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce parathyroid hormone (PTH) level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Parathyroid Hormone (PTH; Percentage Decrease)</title>
          <description>Mean PTHauc (% decrease) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20-29%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 40%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction of Parathyroid Hormone Area Under the Curve (PTHauc) of 20% or Greater</title>
        <description>Clinically significant reduction of Mean PTHauc (% decrease &gt;/= 20) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.</description>
        <time_frame>Measured at baseline and Month 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Paricalcitol (Active Drug)</title>
            <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Parathyroid Hormone Area Under the Curve (PTHauc) of 20% or Greater</title>
          <description>Clinically significant reduction of Mean PTHauc (% decrease &gt;/= 20) for Paricalcitol (Active Drug) and Placebo from Baseline to Month 12.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paricalcitol (Active Drug)</title>
          <description>Participants given active drug, paricalcitol (Zemplar), in effort to reduce PTH level
Paricalcitol: Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants given placebo capsule to match for comparison
Placebo: Placebo sugar pill</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Serum Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas O. Carpenter</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-6526</phone>
      <email>thomas.carpenter@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

